FAM222A encodes Aggregatin, a 47-kDa protein predominantly expressed in the central nervous system that plays a pathogenic role in Alzheimer's disease (AD) 1. The primary function of Aggregatin involves facilitating amyloid-beta (Aβ) aggregation through direct physical interaction via its N-terminal Aβ binding domain 12. Mechanistically, Aggregatin accumulates within amyloid plaques and stabilizes Aβ peptide assembly, with molecular dynamics simulations confirming stable protein-peptide complexes 3. In disease pathology, FAM222A was identified as a brain atrophy susceptibility gene through imaging genetics analysis 1. Elevated Aggregatin expression occurs in AD patient brains and mouse models, with reactive astrocytes identified as primary cellular sources 4. Functionally, intracerebroventricular infusion or forced expression exacerbates neuroinflammation and cognitive dysfunction in AD models, whereas FAM222A ablation suppresses amyloid deposit formation, neuroinflammation, and cognitive deficits 1. Clinically, FAM222A co-expression correlates with multiple AD-related pathway genes across brain tissues 5, suggesting coordinated involvement in disease pathogenesis. Virtual screening identified potential therapeutic candidates (Cefpiramide, Diniprofylline, Fostriecin, Droperidol) targeting Aggregatin 6, indicating therapeutic potential in AD intervention strategies.